AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Cyber startup Cyera eyes $20 billion valuation in new funding talks
2
"A gorgeous situation": ServiceNow's CEO celebrates a shrinking workforce
3
Stealth Israeli cyber startup valued at over $1.5 billion recruits former 8200 chief
4
Intel’s $600 million question: How the Kiryat Gat explosion hit its forecast
5
Nikesh Arora's pay falls 19.5% to $80 million as Palo Alto Networks board lowers cap on stock awards
More news

Generic Drugs

13 stories about Generic Drugs
בניין חברת טבע בכפר סבא לצד מנכ"ל טבע ריצ'רד פרנסיס

Teva’s comeback is real. The harder part is still ahead

22.09.26|Sophie Shulman
The company has cleaned up its balance sheet and rebuilt its pipeline, but investors are still waiting to see whether the new strategy can deliver sustained growth.
קאר שולץ מנכל טבע

Teva Investors Are Back on the Rollercoaster

27.09.18|Lilach Baumer
The stock of Teva Pharmaceutical Industries Ltd. fell over 11% on NYSE between September 20 and Thursday, bringing a halt to a nearly two weeks rally
ה מטה הנוכחי של טבע ב ארה"ב

Mylan Cuts Price of Generic Copaxone Offering by 60%

11.07.18|Lilach Baumer
Mylan has achieved a 15%-20% market share in the U.S. since launching its generic version in late 2017 with a monthly price tag of $5,000, compared to Teva's $5,800
מנכ"ל טבע החדש קור שולץ 2

Teva Shut Down New York, Washington Offices, Says CEO

23.02.18|Dror Reich
In a meeting with investors in Israel, CEO Kåre Schultz said the Washington offices were used mainly by lobbyists, for which Teva has no further need
מנכ"ל טבע החדש קור שולץ 2

As Part of Cost-Cutting Plan, Teva Will Shut Down Twenty or More Manufacturing Sites

10.01.18|Lilach Baumer
The drugmaker will shut down 20-25 manufacturing sites in the next two years, CEO Kåre Schultz said Monday
אינפו טבע מחירי תרופות גנריות Teva generic drug prices

The Crucial Piece of Information Teva Overlooked

24.12.17|Sophie Shulman
When Teva went full force after Allergan's generic unit Actavis in what has become the company’s most costly acquisition, generic drug prices were already falling.
מנכ"ל טבע החדש קור שולץ

New CEO Steers Teva Back to Generics

28.11.17|Golan Hazani and Dror Reich
A reorganization plan announced by the company Monday would see the troubled drugmaker return to its core competencies, despite market pressures
ראג'יב מאליק נשיא מיילן

Investors Cheer as Mylan Plans to Delist from Israeli Stock Exchange

12.11.17|Uri Tal-Tenne and Dror Reich
Mylan is currently the highest valued company on the TASE at $18.5 billion
מנכ"ל טבע החדש קור שולץ 2

Generic Dependence Threatens Teva’s Ability to Haul Debt Load

05.11.17|Dror Reich and Lilach Baumer
Teva’s stock price dropped 18.7% last week after the company lowered its annual forecasts. On Friday, S&P changed the company’s outlook to negative
מנכ"ל טבע החדש קור שולץ

New CEO to Take Helm at Troubled Teva Wednesday

31.10.17|Lilach Baumer
The generic drugmaker shed 67% of its market price over the last 12 months
חברת ה תרופות טבע Teva

Teva’s Stock Drops After Approval of Copaxone Competitors

08.10.17|Lilach Baumer
A day after Mylan announced FDA approval for its generic versions of Copaxone, drug companies Synthon and Alvogen announce European approval for their 40 mg/ml generic versions of Teva's blockbuster drug
מפעל טבע הר חוצבים ירושלים

Cerberus, Advent Eye Teva's European Assets, Report Says

15.08.17|Calcalist
The private equity firms are taking an interest in Teva's European oncology and pain treatment assets, estimated at $700 million to 1$ billion, according to a Bloomberg report
תרופות טבע גלולות תרופה

With Bloated Debt, Teva Looks to Sell Assets

10.08.17|Eli Shimony and Gil Kalian
The generic drugmaker said it is looking to sell Medis, an Iceland-based company it bought in 2016